SS

Satendra Singh

Active Director Director DIN 02926852
DIN 02926852 First appointment Mar 2010 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2010
Shareholding value •••• Premium profile

About Satendra Singh

Data last updated:

Satendra Singh is a Director at Avert Pharma Private Limited (since 2010). The company operates in Pharma. Avert Pharma Private Limited reported revenue of ₹54.6 Lakh (FY 2024).

DIN 02926852
Primary Designation Director
Industry Pharma
First Appointment 10 Mar 2010
Oldest Company Age 16 yrs
Largest company Avert Pharma Private Limited · ₹54.6 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Avert Pharma Private Limited U36101DL2010PTC199918
Director10 Mar 20102010₹54.6 Lakh (FY 2024)Active

Board colleagues of Satendra Singh

NameDINCompanyDesignation
Satish Chand02926684Avert Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Avert Pharma Private Limited
Premium access

Shareholding and investment profile for Satendra Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Satendra Singh

Satendra Singh currently holds 1 directorship: Avert Pharma Private Limited (Director, since 10 Mar 2010, revenue ₹54.6 Lakh (FY 2024)).

Satendra Singh was first appointed on 10 Mar 2010 as Director at Avert Pharma Private Limited.

The current boards of Satendra Singh's companies include Satish Chand (Avert Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available